Collegium Pharmaceutical, Inc. COLL Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $796.33M+19.9% | $780.57M+23.6% | $757.07M+26.3% | $707.01M+22.6% | $664.28M+17.2% | ||
| $313.15M+11.4% | $317.31M+24.9% | $323.9M+43.6% | $306.22M+39.5% | $281.07M+24.0% | ||
| $483.18M+26.1% | $463.26M+22.8% | $433.17M+15.9% | $400.79M+12.2% | $383.21M+12.6% | ||
| 60.7%+3.0pp | 59.3%-0.4pp | 57.2%-5.1pp | 56.7%-5.3pp | 57.7%-2.3pp | ||
| $294.73M+20.4% | $284.8M+35.4% | $280.25M+55.5% | $275.11M+79.2% | $244.8M+64.9% | ||
| $294.33M+22.1% | $283.62M+36.7% | $276.18M+53.2% | $271.05M+76.5% | $241.1M+62.5% | ||
| $294.33M+22.1% | $283.62M+36.7% | $276.18M+53.2% | $271.05M+76.5% | $241.1M+62.5% | ||
| $188.85M+32.9% | $179.64M+5.7% | $156.99M-18.9% | $129.74M-36.3% | $142.11M-25.9% | ||
| 23.7%+2.3pp | 23%-3.9pp | 20.7%-11.5pp | 18.4%-17.0pp | 21.4%-12.4pp | ||
| $77.38M-0.1% | $82.31M+11.3% | $85.67M+21.3% | $82.3M+12.8% | $77.43M-2.3% | ||
| $12.77M+9.0% | $11.29M-19.2% | $9.54M-42.1% | $9.7M-45.3% | $11.71M-32.5% | ||
| $108.24M+66.3% | $92.62M-6.0% | $80.85M-36.8% | $53M-62.5% | $65.07M-49.9% | ||
| $33.29M+57.2% | $29.75M+1.3% | $22.41M-43.1% | $16.73M-59.5% | $21.17M-42.2% | ||
| $74.95M+70.7% | $62.87M-9.1% | $58.44M-34.0% | $36.27M-63.7% | $43.89M-53.0% | ||
| 9.4%+2.8pp | 8.1%-2.9pp | 7.7%-7.1pp | 5.1%-12.2pp | 6.6%-9.8pp | ||
| $2.04+67.2% | $1.71-8.1% | $1.61-30.6% | $1.04-59.7% | $1.22-49.2% | ||
| $2.37+74.3% | $2.00-6.5% | $1.85-32.5% | $1.14-62.7% | $1.36-52.1% | ||
| 158.7M+3.4% | 151.4M-6.6% | 151.5M-7.2% | 152.2M-7.9% | 153.5M-8.4% | ||
| 127.1M-1.1% | 126.8M-1.8% | 127.3M-1.6% | 127.9M-2.2% | 128.6M-3.3% | ||
| —— | —— | —— | —— | $179.45M+19.1% | ||
| -$396K+89.3% | -$1.18M+59.4% | -$4.08M— | -$4.06M— | -$3.7M— | ||
| $12.77M+9.0% | $11.29M-19.2% | $9.54M-42.1% | $9.7M-45.3% | $11.71M-32.5% | ||
| $796.33M+19.9% | $780.57M+23.6% | $757.07M+26.3% | $707.01M+22.6% | $664.28M+17.2% | ||
| $188.85M+32.9% | $179.64M+5.7% | $156.99M-18.9% | $129.74M-36.3% | $142.11M-25.9% | ||
| $247.87M-25.4% | $239.29M-29.4% | $272.23M-20.3% | $285.7M-17.7% | $332.4M-1.7% | ||
| $247.87M-25.4% | $239.29M-29.4% | $272.23M-20.3% | $285.7M-17.7% | $332.4M-1.7% | ||
| 31.1%-18.9pp | 30.7%-23.0pp | 36%-21.0pp | 40.4%-19.8pp | 50%-9.6pp | ||
| $188.85M+32.9% | $179.64M+5.7% | $156.99M-18.9% | $129.74M-36.3% | $142.11M-25.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Collegium Pharmaceutical, Inc.'s revenue?
- Collegium Pharmaceutical, Inc. (COLL) generated $796.3M in revenue over the trailing twelve months, up 19.9% year over year.
- Is Collegium Pharmaceutical, Inc. profitable?
- Collegium Pharmaceutical, Inc. reported $74.9M in net income over the trailing twelve months, a 9.4% net margin.
- What are Collegium Pharmaceutical, Inc.'s profit margins?
- Gross margin is 60.7% and operating margin is 23.7%, with a 9.4% net margin.
- What is Collegium Pharmaceutical, Inc.'s earnings per share?
- Collegium Pharmaceutical, Inc.'s diluted EPS over the trailing twelve months is $2.04.
- Where does Collegium Pharmaceutical, Inc.'s income statement data come from?
- Every line is extracted from Collegium Pharmaceutical, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
